Lymphoma & Leukaemia Watch 43 – Follicular lymphoma into the future
Lymphoma & Leukaemia Research Review, Issue 94
ESMO Clinical practice guideline interim update on the new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia
https://vimeo.com/1088903243 Fit and unfit patients in CLL https://vimeo.com/1088903134 Chemotherapy and novel targeted agents https://vimeo.com/1088902956 Continuous or time-limited treatment? https://vimeo.com/1088902844 TP53 mutation and BTKis Disclaimer: Thanks for listening to this educational podcast initiated and sponsored by AbbVie Pty Ltd (“AbbVie”). The individual opinions expressed within the videos may not represent the views of AbbVie. AbbVie does […]
BSH Highlights 2025
Lymphoma & Leukaemia Watch 42 – Odronextamab for DLBCL
Product Review – Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
Lymphoma & Leukaemia Research Review, Issue 93
Professor Michael Dickinson discusses CAR T-Cell Therapy: Axicabtagene Ciloleucel for Second-Line Treatment of Relapsed or Refractory Large B-Cell Lymphoma
https://vimeo.com/1073445619https://vimeo.com/1073446157https://vimeo.com/1073446868https://vimeo.com/1073447292
Lymphoma & Leukaemia Watch 41 – Novel approaches in T cell lymphoma
ASH Highlights 2024 focus on Lymphoma & Leukaemia
CPD Home. Subscribers can claim the time spent watching videos and evaluating research reviews as an Educational Activity: Professional Reading in the CPD Tracker. Please Contact Us for support. Royal Australasian College of Physicians (RACP) MyCPD participants can claim the time spent watching videos and evaluating research reviews as CPD in the online MyCPD program.
